Drug Trial Radar · NCT01531192
Comparison of Lactobacillus Reuteri and Nystatin Prophylaxis on Candida Colonization and Infection in Very Low Birth Weight Infants
Last checked: Nov 19, 2026Latest source record: Jul 16, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Jun 2012
Primary completion
Apr 2013
Study completion Apr 2013
Sponsor
- Lead sponsor
- Zekai Tahir Burak Women's Health Research and Education HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 10, 2012
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 1 day, up to 6 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Probiotics are favorable microorganisms that regulate the flora of the gastrointestinal system and stimulate the immune system. Lactobacillus reuteri was shown to reduce candida colonization. The objective of this study is to evaluate the efficacy of prophylactic Lactobacillus reuteri in reducing the candida colonization and infection in very low birth weight infants.
Conditions
- Very Low Birth Weight Infants
Interventions
Lactobacillus reuteriDietary supplement
Lactobacillus reuteri 100 million CFU/day for 3 months
NystatinDrug
50000 unit/3 times a day, both for orally and by orogastric route
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of prophylactic Lactobacillus reuteri and nystatin on candida colonization and infection in very low birth weight infantsTime frame: up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zekai Tahir Burak Maternity Teaching Hospital, Division of Neonatology
Ankara, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.